-
1
-
-
70949107842
-
Inflammatory bowel disease
-
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
-
(2009)
N Engl J Med
, vol.361
, pp. 2066-2078
-
-
Abraham, C.1
Cho, J.H.2
-
2
-
-
0142053206
-
The immunological and genetic basis of inflammatory bowel disease
-
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
-
(2003)
Nat Rev Immunol
, vol.3
, pp. 521-533
-
-
Bouma, G.1
Strober, W.2
-
3
-
-
33847381116
-
The fundamental basis of inflammatory bowel disease
-
Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
-
(2007)
J Clin Invest
, vol.117
, pp. 514-521
-
-
Strober, W.1
Fuss, I.2
Mannon, P.3
-
5
-
-
0025779160
-
Tumor necrosis factor, new insights into the molecular mechanisms of its multiple actions
-
Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
-
(1991)
J Biol Chem
, vol.266
, pp. 7313-7316
-
-
Vilcek, J.1
Lee, T.H.2
-
6
-
-
19644375686
-
Molecular mechanism of TNF signaling and beyond
-
Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15:24-27.
-
(2005)
Cell Res
, vol.15
, pp. 24-27
-
-
Liu, Z.G.1
-
7
-
-
0032833517
-
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
-
Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
-
(1999)
Gastroenterology
, vol.117
, pp. 761-769
-
-
Rutgeerts, P.1
D'Haens, G.2
Targan, S.3
-
8
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
-
9
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
-
10
-
-
33846242958
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
-
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
-
(2007)
Gastroenterology
, vol.132
, pp. 52-65
-
-
Colombel, J.F.1
Sandborn, W.J.2
Rutgeerts, P.3
-
11
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
-
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
Van Deventer, S.J.3
-
12
-
-
62949219864
-
Biological therapies for inflammatory bowel diseases
-
Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197.
-
(2009)
Gastroenterology
, vol.136
, pp. 1182-1197
-
-
Rutgeerts, P.1
Vermeire, S.2
Van Assche, G.3
-
13
-
-
62049083383
-
Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
-
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 760-767
-
-
Gisbert, J.P.1
Panes, J.2
-
14
-
-
63849251824
-
Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
-
Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
-
(2009)
Gut
, vol.58
, pp. 501-508
-
-
Fidder, H.1
Schnitzler, F.2
Ferrante, M.3
-
15
-
-
0035007746
-
Reactivation tuberculosis in a patient with anti-TNF-alpha treatment
-
Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001;96:1665-1666.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 1665-1666
-
-
Nunez, M.O.1
Ripoll, N.C.2
Carneros, M.J.A.3
-
16
-
-
67650430007
-
Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
-
Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253-264.
-
(2009)
Aliment Pharmacol Ther
, vol.30
, pp. 253-264
-
-
Schneeweiss, S.1
Korzenik, J.2
Solomon, D.H.3
-
17
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
-
quiz 591
-
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
-
18
-
-
0026461349
-
Genomic structure, induction, and production of TNF-alpha
-
Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-alpha. Immunol Ser. 1992;56:3-34.
-
(1992)
Immunol Ser
, vol.56
, pp. 3-34
-
-
Spriggs, D.R.1
Deutsch, S.2
Kufe, D.W.3
-
19
-
-
0024281428
-
A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
-
Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
-
(1988)
Cell
, vol.53
, pp. 45-53
-
-
Kriegler, M.1
Perez, C.2
Defay, K.3
-
20
-
-
0028483534
-
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor
-
McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994;370:558-561.
-
(1994)
Nature
, vol.370
, pp. 558-561
-
-
McGeehan, G.M.1
Becherer, J.D.2
Bast Jr., R.C.3
-
21
-
-
8044250278
-
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
-
Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736.
-
(1997)
Nature
, vol.385
, pp. 733-736
-
-
Moss, M.L.1
Jin, S.L.2
Milla, M.E.3
-
22
-
-
0036288520
-
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
-
Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51:37-43.
-
(2002)
Gut
, vol.51
, pp. 37-43
-
-
Brynskov, J.1
Foegh, P.2
Pedersen, G.3
-
23
-
-
0035931044
-
Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis
-
Colon AL, Menchen LA, Hurtado O, et al. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine. 2001;16:220-226.
-
(2001)
Cytokine
, vol.16
, pp. 220-226
-
-
Colon, A.L.1
Menchen, L.A.2
Hurtado, O.3
-
24
-
-
5644290647
-
Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17)
-
Zheng Y, Saftig P, Hartmann D, et al. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem. 2004;279:42898-42906.
-
(2004)
J Biol Chem
, vol.279
, pp. 42898-42906
-
-
Zheng, Y.1
Saftig, P.2
Hartmann, D.3
-
25
-
-
4744375545
-
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD
-
Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
-
(2004)
Gastrointest Endosc
, vol.60
, pp. 505-512
-
-
Daperno, M.1
D'Haens, G.2
Van Assche, G.3
-
26
-
-
0023521441
-
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
-
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
-
(1987)
N Engl J Med
, vol.317
, pp. 1625-1629
-
-
Schroeder, K.W.1
Tremaine, W.J.2
Ilstrup, D.M.3
-
27
-
-
0034894059
-
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease
-
Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
-
(2001)
J Clin Invest
, vol.108
, pp. 601-609
-
-
Monteleone, G.1
Kumberova, A.2
Croft, N.M.3
-
28
-
-
0037073443
-
Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/disintegrinmetalloproteinase 19 is necessary for its proteolytic activity
-
Kang T, Park HI, Suh Y, et al. Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/ disintegrinmetalloproteinase 19 is necessary for its proteolytic activity. J Biol Chem. 2002;277:48514-48522.
-
(2002)
J Biol Chem
, vol.277
, pp. 48514-48522
-
-
Kang, T.1
Park, H.I.2
Suh, Y.3
-
29
-
-
0027451455
-
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
-
Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
-
(1993)
Clin Exp Immunol
, vol.94
, pp. 174-181
-
-
Reinecker, H.C.1
Steffen, M.2
Witthoeft, T.3
-
30
-
-
0033125226
-
Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
-
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
-
(1999)
Inflamm Bowel Dis
, vol.5
, pp. 119-133
-
-
Sandborn, W.J.1
Hanauer, S.B.2
-
31
-
-
69249159918
-
ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases
-
Qi B, Newcomer RG, Sang QX. ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases. Curr Pharm Des. 2009;15:2336-2348.
-
(2009)
Curr Pharm des
, vol.15
, pp. 2336-2348
-
-
Qi, B.1
Newcomer, R.G.2
Sang, Q.X.3
-
32
-
-
0037067764
-
Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites
-
Kang T, Zhao YG, Pei D, et al. Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J Biol Chem. 2002; 277:25583-25591.
-
(2002)
J Biol Chem
, vol.277
, pp. 25583-25591
-
-
Kang, T.1
Zhao, Y.G.2
Pei, D.3
-
33
-
-
0034643292
-
Meltrin beta (ADAM19) gene: Cloning, mapping, and analysis of the regulatory region
-
Kurohara K, Matsuda Y, Nagabukuro A, et al. Meltrin beta (ADAM19) gene: cloning, mapping, and analysis of the regulatory region. Biochem Biophys Res Commun. 2000;270:522-527.
-
(2000)
Biochem Biophys Res Commun
, vol.270
, pp. 522-527
-
-
Kurohara, K.1
Matsuda, Y.2
Nagabukuro, A.3
-
34
-
-
0034815337
-
Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta
-
Wei P, Zhao YG, Zhuang L, et al. Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. Biochem Biophys Res Commun. 2001;280:744-755.
-
(2001)
Biochem Biophys Res Commun
, vol.280
, pp. 744-755
-
-
Wei, P.1
Zhao, Y.G.2
Zhuang, L.3
-
35
-
-
77953289538
-
ADAM19 autolysis is activated by LPS and promotes non-classical secretion of cysteine-rich protein 2
-
Tanabe C, Hotoda N, Sasagawa N, et al. ADAM19 autolysis is activated by LPS and promotes non-classical secretion of cysteine-rich protein 2. Biochem Biophys Res Commun. 2010;396:927-932.
-
(2010)
Biochem Biophys Res Commun
, vol.396
, pp. 927-932
-
-
Tanabe, C.1
Hotoda, N.2
Sasagawa, N.3
-
36
-
-
22144454605
-
Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2
-
Horiuchi K, Zhou HM, Kelly K, et al. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol. 2005;283:459-471.
-
(2005)
Dev Biol
, vol.283
, pp. 459-471
-
-
Horiuchi, K.1
Zhou, H.M.2
Kelly, K.3
-
37
-
-
0035937787
-
Roles of meltrin beta/ADAM19 in the processing of neuregulin
-
Shirakabe K, Wakatsuki S, Kurisaki T, et al. Roles of Meltrin beta/ADAM19 in the processing of neuregulin. J Biol Chem. 2001;276:9352-9358.
-
(2001)
J Biol Chem
, vol.276
, pp. 9352-9358
-
-
Shirakabe, K.1
Wakatsuki, S.2
Kurisaki, T.3
-
38
-
-
0346851877
-
Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation
-
Fritsche J, Muller A, Hausmann M, et al. Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. Immunology. 2003;110:450-457.
-
(2003)
Immunology
, vol.110
, pp. 450-457
-
-
Fritsche, J.1
Muller, A.2
Hausmann, M.3
-
39
-
-
33748946027
-
ADAM19 expression in human nephrogenesis and renal disease: Associations with clinical and structural deterioration
-
Melenhorst WB, van den Heuvel MC, Timmer A, et al. ADAM19 expression in human nephrogenesis and renal disease: associations with clinical and structural deterioration. Kidney Int. 2006;70:1269-1278.
-
(2006)
Kidney Int
, vol.70
, pp. 1269-1278
-
-
Melenhorst, W.B.1
Van Den Heuvel, M.C.2
Timmer, A.3
-
41
-
-
3242799873
-
Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome
-
Roemer A, Schwettmann L, Jung M, et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. 2004;11:529-536.
-
(2004)
Oncol Rep
, vol.11
, pp. 529-536
-
-
Roemer, A.1
Schwettmann, L.2
Jung, M.3
-
42
-
-
63949084246
-
Expression, of ADAMs ("a disintegrin and metalloprotease") in the human lung
-
Dijkstra A, Postma DS, Noordhoek JA, et al. Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch. 2009;454:441-449.
-
(2009)
Virchows Arch
, vol.454
, pp. 441-449
-
-
Dijkstra, A.1
Postma, D.S.2
Noordhoek, J.A.3
-
43
-
-
33847202635
-
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies
-
Dehmel T, Janke A, Hartung HP, et al. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis. 2007;25:665-674.
-
(2007)
Neurobiol Dis
, vol.25
, pp. 665-674
-
-
Dehmel, T.1
Janke, A.2
Hartung, H.P.3
-
44
-
-
33745689524
-
Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness
-
Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006;65:516-527.
-
(2006)
J Neuropathol Exp Neurol
, vol.65
, pp. 516-527
-
-
Wildeboer, D.1
Naus, S.2
Amy, S.Q.X.3
|